Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
100%(5 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_4
1
14%
Ph phase_3
1
14%
Ph not_applicable
1
14%
Ph phase_2
4
57%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (57.1%)
Phase 31 (14.3%)
Phase 41 (14.3%)
N/A1 (14.3%)

Trials by Status

withdrawn114%
terminated114%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
completednot_applicable

Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C

NCT00252642
completedphase_4

Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

NCT02761629
completedphase_2

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

NCT00874770
completedphase_2

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

NCT01074008
completedphase_2

Pegylated Interferon to Treat Chronic Hepatitis D

NCT00023322
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00252642Not Applicable

Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C

Completed
NCT02761629Phase 4

Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

Completed
NCT00874770Phase 2

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Completed
NCT01074008Phase 2

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Completed
NCT00023322Phase 2

Pegylated Interferon to Treat Chronic Hepatitis D

Completed
NCT00412750Phase 3

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

Terminated
NCT01142700Phase 2

A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7